Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Treatment of myotubes with IL-6, IL6R, and IL-6 and palmitate

JR Joseph E. Rupert
AN Ashok Narasimhan
DJ Daenique H.A. Jengelley
YJ Yanlin Jiang
JL Jianguo Liu
EA Ernie Au
LS Libbie M. Silverman
GS George Sandusky
AB Andrea Bonetto
SC Sha Cao
XL Xiaoyu Lu
TO Thomas M. O’Connell
YL Yunlong Liu
LK Leonidas G. Koniaris
TZ Teresa A. Zimmers
request Request a Protocol
ask Ask a question
Favorite

Myotubes were maintained in DF and treated with either PBS (control), recombinant mouse IL-6 (300 pg/ml; 406-ML-005; R&D Systems), recombinant mouse IL6R (25 ng/ml; P9767-5G; Sigma Aldrich), and the combination of IL-6 (300 pg/ml) and IL6R (25 ng/ml) for 48 h. After 48 h, myotubes were fixed, and mean minimum diameters were measured as previously described herein.

Separately, myotubes were maintained in DF and treated with either PBS (control), recombinant mouse IL-6 (20 ng/ml; 406-ML-005; R&D Systems), palmitate (0.5 mM; P9767-5G; Sigma Aldrich) conjugated to BSA in a 5:1 molar ratio, or the combination of IL-6 (20 ng/ml) and palmitate (0.5 mM) for 48 h. After 48 h, myotubes were fixed, and mean minimum diameters were measured as previously described herein.

Copyright and License information:  ©2021 Rupert et al.
This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A